Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Open accessThe DOI matches its Crossref record; 265 of the 268 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, SLNs utilize receptor-mediated and adsorptive-mediated transcytosis to cross the BBB and enable sustained drug release [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SLNs can effectively transport drugs across the BBB, enabling the delivery of compounds that are otherwise impermeable [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759 · cited 3×
“These features make SLNs advantageous for production on a large industrial scale [43].”
InfluentialSacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569 · cited 1×
“There are several types of ischemic strokes, such as lacunar, cardioembolic, and cryptogenic strokes, and hemorrhagic strokes [259].”
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150 · cited 2×
“SLNs can also be synthesized by ultrasonication [120,170,173] (Figure 7) in an easily assessable way, to overcome the limitations of high-shear homogenization.”
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · cited 1×
“The essential neurovascular unit cell types that contribute to the functionality of the BBB are endothelial cell adhesion molecules, pericytes, smooth muscle cells, astrocytes, and micro glia, etc., which form the BBB, a complex barrier unit [13–16].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death
Choi, D. W., & Rothman, S. M. (1990) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.13.030190.001131 · Cited by 2,223
Animal Communication: When I’m Calling You, Will You Answer Too?
Vickers, N. J. (2017) · Current Biology · doi:10.1016/j.cub.2017.05.064 · Cited by 2,210
Research works printed but not linked: 8
- Dingler A. Feste Lipid-Nanopartikel als Kolloidale Wirkstoffträgersysteme zur Dermalen Applikation Ph.D. Thesis Freie Universität Berlin Berlin, Germany 1998
- Müller R. Schwarz C. Zur Mühlen A. Mehnert W. Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles (SLN) Proceedings of International Symposium on Controlled Release of Bioactive Materials Nice, France 27–30 June 1994 146 147 · DOI · Paper page
- Zur Mühlen A. Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles Pharmazie 1998 53 552 555 9704911
- zur Muhlen A. Feste Lipid Nanopartikel mit Prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und Mechanismen Ph.D. Thesis Free University of Berlin Berlin, Germany 1996
- Meyer W. Wettkampf und Spiel in den Miniaturen der Manessischen Liederhandschrift Stadion 1988 14 1 48
- Nelluri S. Felix J. Sathesh K. Formulation and evaluation of galantamine nanoparticles for neurological disorders Int. J. Pharm. Chem. Biol. Sci. 2015 5 63 70
- Özdemir Y.G. Pehlivan S.B. Sekerdag E. Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery Across the Blood–Brain Barrier Academic Press Cambridge, MA, USA 2017
- Duarte A.M.G. Resveratrol and Grape’s Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson’s and Alzheimer’s Diseases Master’s Thesis Faculty of Engineering of University of Porto Porto, Portugal 2015
Cited by
Items 201–300 of 319
Geremamo, Y. D., Hasan, A., Razzak, S. A., & Uddin, S. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126604 · Cited by 4
Kalaycıoğlu, G. D., Altas, B. O., & Aydoğan, N. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2634669 · Cited by 2
Mishra, A., Satapathy, B. S., & Sahu, P. K. (2026) · Discover Nano · doi:10.1186/s11671-026-04528-3 · Cited by 4
Rahman, M. M., & Rahman, M. M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108393 · Cited by 2
Suriyaamporn, P., Wongprayoon, P., Pannakkong, W., Pamornpathomkul, B., Ngawhirunpat, T., Rojanarata, T., & Opanasopit, P. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126967 · Cited by 2
Sumalatha, K., & Gandhimathi, R. (2026) · Nano Trends · doi:10.1016/j.nwnano.2026.100215 · Cited by 2
Potential Toxicity of Nanoparticles for the Oral Delivery of Therapeutics
Alfagih, I. M. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.111946 · Cited by 2
Nanomaterials for Diagnosis and Treatment of Common Neurological Disorders
Kaur, G., Chirayimmel, A. J., Rana, P., Sharma, S., Bose, J. C., Rath, S. K., & Dwibedi, V. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0308-1_8 · Cited by 4
p, R., Prajapati, B. G., Rajeshkumar, R., Balasubramaniam, V., & Ponnusankar, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673314366240712105637 · Cited by 2
Kharazmi, F., Neamati, A., & Tabrizi, M. H. (2024) · BioNanoScience · doi:10.1007/s12668-024-01746-w · Cited by 3
“Solid lipid nanoparticles (SLNs) have emerged as a promising alternative to traditional drug administration methods, such as oral or intravenous routes [6].”
Nanostructure-Based Drug Delivery in Alleviating Type 2 Diabetes Mellitus
Saini, A., Nagar, L., Panwar, R., Pahwa, R., Dua, K., Dureja, H., & Verma, P. K. (2025) · BioNanoScience · doi:10.1007/s12668-024-01786-2 · Cited by 2
“SLNs are highly effective for encapsulation of hydrophobic (lipophilic) drugs [60].”
Almajidi, Y. Q., Muslim, R. K., & khalf, Y. T. (2025) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v25i1.1065 · Cited by 2
Facilitating DNAzyme transport across the blood-brain barrier with nanoliposome technology
Hoseinifar, M. J., Aghaz, F., Asadi, Z., Asadi, P., Nedaei, S. E., Arkan, E., Pourmotabbed, A., Bahrami, G., & Pourmotabbed, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-04433-2 · Cited by 5
“Specifically, nanoliposomes have gained attention as a drug delivery system that has the potential to deliver drugs to the specific target sites of the brain after passing the BBB effectively, using particular pathways 22–24 .”
Role of Galangin for the Treatment of Alzheimer’s Disease: Journey So Far and Road Ahead
Sharma, P., Sharma, T., Bashir, B., andotra, N., Awasthi, A., Patel, P. V., Subramaniyan, V., Chellappan, D. K., Gupta, G., Vishwas, S., et al. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00669-6 · Cited by 3
“The versatile nature of SLNs broadens their applicability across various therapeutic areas, and the small particle size and surface modifications that promote receptor-mediated endocytosis facilitate their crossing the BBB [114].”
Babaker, M. A., Ghany, K. A. E., Elshafey, N., Algohary, A. M., Elgohary, E., Hamouda, R. A., Abol-Fetouh, G. M., Elbawab, R. H., & Ahmed-Farid, O. A.-H. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107194 · Cited by 2
Surface Active Ligands for Enhanced Brain Targeting of Nanoparticles
Prabakaran, A., Vashist, R., Sangave, S. D., & Alexander, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_9 · Cited by 3
Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083560 · Cited by 1
“Each class possesses unique properties: lipid particles (liposomes, exosomes) offer biocompatibility [23–25]; polymeric particles (Poly(lactic-co-glycolic acid) (PLGA), dendrimers) provide biodegradability and functionalization [19,26]; superparamagnetic iron oxide Nps (SPIONs) enable MRI contrast…”
Nanomaterials as Drug Delivery Vehicles for Therapy of Parkinson's Disease
Chirayimmel, A. J., Kaur, G., Rana, P., Rath, S. K., Mandal, S. K., & Dwibedi, V. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0308-1_13 · Cited by 2
Malik, Z., Parveen, R., Basist, P., Husain, S. A., & Ahmad, S. (2024) · BioNanoScience · doi:10.1007/s12668-024-01604-9 · Cited by 1
“Moreover, the interaction of SLNs with the cell membrane can disrupt cellular homeostasis, further contributing to the cytotoxicity of SLNs [57].”
Exploring the state-of-art of lipid nanomedicines for obstructive pulmonary diseases
Sharma, H., Kaushik, M., Ashique, S., Islam, A., Mandal, S., & Mojgani, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22374-7.00010-4 · Cited by 4
Lipid-drug conjugates for enhanced antiretroviral efficacy
Chakraborty, T., Sarma, A., Ghose, S., & Das, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33382-8.00009-1 · Cited by 1
Smart Nanometals: An Approach to Transform Brain Cancer Diagnosis and Therapy
Arora, A., Jain, N., Pandey, M., Kaul, S., Verma, R., & Gorain, B. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00504 · Cited by 2
Harnessing Natural Source Lipids for Advanced Drug Delivery Systems
Purandare, D., Patil, A., Polshettiwar, A. P., Chavan, P., & Polshettiwar, S. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-7959-1_8 · Cited by 1
Garg, G., Singh, A., Patel, P., Kumar, M., Thakur, S., & Kurmi, B. D. (2025) · BioNanoScience · doi:10.1007/s12668-025-02232-7 · Cited by 2
“The results comply with the (Satapathy et al., 2021) findings which say that there occurs an electrostatic interaction between the charged molecule and the negatively charged luminal membrane of brain endothelial cells [35].”
Khalid, H., Mazhar, D., Zeb, A., Nayab, D. E., Afzal, I., Ali, H., Shah, F. A., & Khan, S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107788 · Cited by 2
Research trends and hotspots of nanomaterials in Alzheimer's disease: bibliometric analysis
Ran, Z., Yang, L.-L., Zhou, L.-Y., Wen, T., Wang, W., & Chen, L. (2026) · Discover Nano · doi:10.1186/s11671-026-04437-5 · Cited by 1
“These modifications result in significantly elevated drug concentrations in the central nervous system of AD models, offering a promising pathway for treating neurodegenerative disorders [48–51].”
Vojdanitalab, K., Naderi, M., Kalkhajeh, S. G., Sabetghadam, A., & Pashaki, S. R. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108200 · Cited by 4
Brain delivery of lipid nanoparticles with shuttle peptides
Martínez-Martínez, N., CARRERA-RODRÍGUEZ, L., Vargas, R., Hernández-Munaín, C., Suñé-Pou, M., & Suñé, C. M. I. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.02.005 · Cited by 1
Tavares, T. G., Carvalho, I., Ramalho, M. J., Andrade, S., Pereira, M. C., & Loureiro, J. A. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1778124 · Cited by 1
“The in vitro antioxidant capacity of the peptide extract concentrate was determined using the oxygen radical absorbance capacity (ORAC-FL) assay, which evaluates peroxyl radical scavenging capacity with fluorescein (FL) as a fluorescent probe (Satapathy et al., 2021).”
Targeted drug delivery in cardiovascular therapy: Advancements in nanoparticle‐based systems
khafaji, A. T. A., Barakat, A. M., Zaidy, A. J. A., Khafaji, A. A. A., & Aouadi, R. F. A. A. (2026) · Polymer International · doi:10.1002/pi.70111 · Cited by 1
Das, B., Umashankar, M. S., & Madar, I. H. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10676-x · Cited by 1
“The resulting SLN dispersion was diluted to 100 mL to achieve a drug concentration of 0.25 mg/mL [13].”
InfluentialFigueiredo, I., Bicker, J., Vitorino, C., & Fortuna, A. C. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2668677 · Cited by 2
“[ 84 ] C i d o f o v i r S o l u t i o n C y t o m e g a l o v i r u s ( C M V ) i n o c u l a t e d g u i n e a p i g s T h e a d m i n i s t e r e d d r u g e ff e c t i v e l y p e n e t r a t e d t h e r o u n d w i n d o w m e m b r a n e , e n a b l i n g d i r e c t a cc e ss t o t h e i nn…”
Prospects and challenges in intracellular delivery of therapeutic proteins
Sultana, Z., Ahamed, A., Hoda, M., Ali, S., & Hoque, M. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00855-5 · Cited by 1
“Solid lipid nanopar - ticles (SLNs) are lipophilic NPs with a hydrophobic core [ 108 ], allowing easy dispersion across cell membranes.”
Friend or foe? Glial–vascular interactions in health and neurodegenerative disease
McQuaid, C., Sewell, M. D. E., & Montagne, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100143 · Cited by 1
Solid lipid nanoparticles in improving the therapeutic effectiveness of anticancer compounds
Padhiyar, D., Sami, A., Bariya, A., Shah, H., Mehta, T., & Butani, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43826-4.00013-0 · Cited by 1
Nanoparticles that target nonamyloid and nontau pathways in Alzheimer’s disease
Alavian, F., & Hajimohammadi, A. (2026) · Discover Nano · doi:10.1186/s11671-026-04747-8 · Cited by 1
Unuofin, J. O., Aiyegbusi, M. A., Mustapha, A., Adefisan, A. O., Raimi, I. O., Maphetu, N., Nchu, F., Jimoh, M. O., & Lebelo, S. L. (2026) · BioChem · doi:10.3390/biochem6030020 · Cited by 1
“…pharmacological properties, the clinical application of fisetin is limited by several unfavourable physicochemical and pharmacokinetic characteristics, including poor aqueous solubility (approximately 10.45 µ g/mL), high lipophilicity (logP ≈ 3.2), and limited oral bioavailability [1,14–16].”
InfluentialMittal, D., Solanki, P., Jain, G. K., Jhawat, V., Kesharwani, P., Dutt, R., Arora, S., & Singh, R. P. (2026) · 3 Biotech · doi:10.1007/s13205-026-05048-8 · Cited by 1
“Unlike systemic drug delivery, which suffers from poor BBB permeability and systemic metabolism, intranasal administration offers a non-invasive and efficient alterna - tive for neurological disorders such as PD (Satapathy et al. 2021).”
Kanarskii, M. M., Nekrasova, J. Y., Pradhan, P., Borisov, I. V., Korepina, O. S., Kondratyeva, E. A., Nikitkina, A. I., & Petrova, M. V. (2022) · Sleep Medicine Research · doi:10.17241/smr.2022.01361 · Cited by 1
Lipid nanocarriers for the delivery of drugs to the nervous system
Basha, M., AbouSamra, M. M., & Kamel, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95171-5.00005-4 · Cited by 1
Targeting the Blood-Brain Barrier with Nano-Biomaterials
Gowda, S. K., Venkataramanamma, D., & Singh, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-3925-7_3 · Cited by 2
Insights of nose to brain delivery in treating Parkinson’s disease: A systematic review
Renukuntla, P., Tatikayala, R. K., Damera, S., Pathakala, N., & Jadi, R. K. (2024) · Journal of Applied Pharmaceutical Research · doi:10.69857/joapr.v12i6.625 · Cited by 5
Khan, S. A., Qamar, Z., Rohilla, A., Singh, P. P., Parvez, S., Baboota, S., & Ali, J. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128348877241202053633 · Cited by 2
Lipid-Based Nanoparticles for Neurological Drug Discovery
Sathya, C., Sisubalan, N., & Sivamaruthi, B. S. (2025) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-80185-3_11 · Cited by 2
Recent Advances in Rotigotine Nanoformulations for Parkinson’s Disease Therapy
Arora, S., & Gugulothu, D. B. (2025) · BioNanoScience · doi:10.1007/s12668-025-01855-0 · Cited by 1
“This method can enhance the availability of RGT in the brain and enhance the targeting of RGT in the brain [80, 81].”
Recent Trends in Nano-Drug Delivery Systems in the Treatment for Alzheimer ’s Disease
Mejias, S., Sneed, K. B., & Pathak, Y. V. (2025) · Nanotechnology & Applications · doi:10.33425/2639-9466.1037 · Cited by 3
Sultana, A., Shafeeh, A. R., Ahmed, M. G., Biju, P., Sindhu Priya, E. S., & Hussain, M. S. (2025) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073385084250523043452 · Cited by 1
Nano-Enhanced Antibiotic Delivery for Skin Cancer Treatment: A Breakthrough in Nanomedicine
Alanazi, F., Abdulrahman, S., Asiri, O. A., Alasmry, M., Alshahrani, N. A., Aseri, S., Abdualrahim, M., Almuzaini, R., Alotaibi, R., Babalghaith, R., et al. (2025) · Pharmacy Practice · doi:10.18549/pharmpract.2025.2.3117 · Cited by 1
“The solid hydrophobic lipid core of SLN helps in dissipating hydrophilic or lipophilic medicinal products 87 .”
Solid Lipid Nanoparticles as Drug Delivery Carriers for Capsaicin Rich ExtractPreprint
Marinelli, L., Dimmito, M. P., Cacciatore, I., Toto, E. C., Rienzo, A. D., Palmerio, F., Puca, V., Filippo, E. S. D., Fulle, S., & Stefano, A. D. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4487594 · Cited by 1
Recent advances in nanofiber-based systems for acne treatment: A comprehensive reviewPreprint
Tören, E., & Buzgo, M. (2023) · Preprints.org · doi:10.20944/preprints202307.1827.v1
Suryani, A., Affani, A. R., Safitri, B. W., Azis, I. A., Aldo, M. F. E., & Sofia, H. (2021) · Tropical Journal of Natural Product Research · doi:10.21747/21833745/lanlaw8_2a8 · Cited by 1
Bonilla-Vidal, L., Esteruelas, G., Ettcheto, M., Gomara, M. J., Haro, I., Souto, E. B., Espina, M., Camins, A., García, M. L., Cano, A. C., et al. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_18
Sayer, C., Cordeiro, A. P., Arévalo, J. M. C., Feuser, P. E., Assolini, J. P., Kita, D. H., Valdameri, G., Noleto, G. R., Martinez, G. R., Rocha, M. E. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4764954
Formulation and Evaluation of Chitosan Based Sofosbuvir Solid Lipid Nanoparticles
(2023) · NanoWorld Journal · doi:10.17756/nwj.2023-s3-098
“Sofosbuvir has been shown to be more stable, less toxic, biodegradable, more targeted and more biocompatible in solid lipid nanoparticles than in other approved carriers [23].”
Backgroundالنانوسيكولوجي وتطبيقاته في العلوم الإنسانية والطفولة المبكرة
النجار, أ. د. خ. (2024) · Al-Maǧallaẗ Al-Dawliyyaẗ lil- 'ulūm Al-Tarbawiyyaẗ wa Al-Tiknūlūǧiyyaẗ wa Al-Tanmiyyaẗ . · doi:10.21608/ijsetd.2024.360828
Recent Advancements in Lipid Nanocarriers for Brain Delivery of Bioactives
Desai, V. M., Mohanty, S., Priya, S., & Singhvi, G. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_5
Advanced drug delivery systems in the management of CNS disorders
Bidaliya, V., Alam, M. R., Bhratee, A., Kumar, M., Anand, P., Chawla, P. A., & Singh, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00020-2 · Cited by 1
Emerging need of novel drug delivery systems in management of CNS disorders
Tiwari, T., Sinha, A. P., Pandey, M., Chawla, V., Chawla, P. A., & Jain, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00030-5
Barriers to progress of neurotherapeutics: Getting drugs to the brain
Patel, V., Momin, M. M., Mehta, T. A., & Patel, R. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23841-3.00003-0
Nanotherapeutics in Skin Therapy
Chhabra, P., Johari, A., & Tripathy, D. B. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815256505124010011
Rane, B. R., Jain, A. S., Mane, N. P., Patil, V., Patil, M. S., & Bavaskar, K. R. (2024) · Journal of Applied Pharmaceutical Research · doi:10.69857/joapr.v12i6.661
“First, compared to a liquid matrix, a solid matrix has less reactive agent mobility, which could slow the rate of chemical degradation processes [14-16].”
Murshid, N. M., Sahardi, N. F. N. M., & Makpol, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010241 · Cited by 1
“12 of 21 Solid lipid nanoparticles (SLNs) also show promise as a biomimetic strategy for control nervous system (CNS) drug delivery, enhancing BBB penetration and improving drug bioavailability [179]. sites and deliver therapeutic agents [178].”
DUTTA, D., Chakraborty, P., & HOSSAIN, C. M. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i1.52360
“The lowest and highest values obtained from the experiment are indicative of the effect of the concentration of lipids predominantly involved in entrapping the drug in the lipid matrix [46].”
Upcoming Nano and Conventional Drug Delivery Strategies for Alzheimer’s Disease
Varghese, N. M., Sathyamoorthy, N., Krishnamurthy, P. T., Varshini, M. S., & Chintamaneni, P. K. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_16 · Cited by 1
Advances and Trends in Plant-Based Food Bioactives
Lammari, N., Boumaza, M., Louaer, M., Rabti, H., Louaer, O., Elaïssari, A., & Meniai, A. H. (2025) · Springer eBooks · doi:10.1007/978-981-97-9723-3_4
Hu, X., Yang, F., Liao, Y., Lin, L., & Zhang, L. (2025) · Drug Development Research · doi:10.1002/ddr.70069
“Most reports indicated that NPs led to a tentative influx of brain uptake in the first few hours after administration, with reduced levels in the brain measured over time (Satapathy et al. 2021; Zhi et al. 2021).”
Nano lipid-drug conjugates for the treatment of Alzheimer’s disease
Mandal, S., & Das, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33382-8.00010-8
ENHANCING SOLUBILITY AND PERMEABILITY OF HYDROCHLOROTHIAZIDE USING SOLID LIPID NANOPARTICLES
Sabale, V., Telrandhe, R., Ingole, A. R., & Sabale, P. (2025) · INDIAN DRUGS · doi:10.53879/id.62.03.14644
Lipid/Polymer Core-Shell Nanoconstructs for Cancer Theragnostic
Roy, A. A., Naik, G. A. R. R., Pokale, R., Colaco, V., Mukharya, A., Kudarha, R. R., Dhas, N. L., & Mutalik, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-3025-7_11
Kotmakçı, M., Bara, B., Yildirim, Z., Öner, E., Yaman, B., Akalın, T., Özgiray, E., Kosova, B., & Çetintaş, V. B. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107000 · Cited by 4
HOPES AND HURDLES OF DENDRIMERS FOR THE TREATMENT OF PARKINSON’S DISEASE
AGGARWAL, K., Verma, S., RATHORE, A. S., & Parashar, T. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i6.54401
Emerging Developments in Drug Delivery Systems using Solid Lipid Nanoparticles
Bandaru, J., Ullangula, L., Subha Geetha, T., Gayathri, B., & Rao, B. B. (2025) · Journal of Innovations in Applied Pharmaceutical Science (JIAPS) · doi:10.37022/jiaps.v10i2.688
Nanoparticles‐Mediated Delivery of Herbal Actives
Dubey, P., Bharadwaj, S., Richa, S., Kumari, K., Khesarwani, P., & Sharma, S. K. (2025) · Wiley eBooks · doi:10.1002/9781119769484.ch16
Nanonutraceuticals: Applications to Public Health Nutrition
Askari, V. R., Abedi, M. S., Fathani, M., Rahmanian‐Devin, P., & Rahimi, V. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-32047-7_80-1
Lipid-based nanocarrier(s) as delivery vehicles for brain tumor therapy
Dubey, B., Singh, K., Agrawal, P., & Pandey, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33319-4.00001-x · Cited by 1
Technological Advancements in Drug Formulation and Delivery: Revolutionizing Therapeutic Outcomes
Kaur, T., Dushyant, Sharma, T., & Dhingra, A. K. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128388316251001042422
Molla, A. (2025) · American Journal of Polymer Science and Technology · doi:10.11648/j.ajpst.20251102.11
Mettilda, A. P., & Sumithra, M. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.11.003
Kumari, S., Gogikar, S. K., Dikundwar, A. G., Dubey, S. K., & Taliyan, R. (2025) · Chromatographia · doi:10.1007/s10337-025-04453-0
“The SLNs of DB and RP were prepared utilizing the solvent emulsification evaporation method [35].”
Self-citationFuture perspectives and challenges on nanobiomedicine and gastrointestinal diseases
Banigo, A. T., & Obasi, C. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34039-0.00012-3
Abioye, A. O. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00005-3
T., N., DHARA, S., MANNA, P., & Kayal, P. (2026) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i1.56603 · Cited by 4
Yadav, R., Mani, R. J., SHARMA, A. K., KUMAR, A., & Katare, D. P. (2026) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i1.56212 · Cited by 1
Badal, R., Kaur, B., Singh, H., Sharma, P., Yadav, P., Mahapatra, A., Ghildiyal, S., Patel, A. K., Kumar, L., Sharma, B., et al. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111742
Utilizing nanotechnology to diagnose and treat central nervous system disorders
Shahabinejad, E., Shakoeizadeh, A., Karimabad, M. N., Asadi, F., Heydari, M., & Rabori, M. S. (2026) · Neurological Sciences · doi:10.1007/s10072-025-08750-2
“Furthermore, it has been shown that lipid-and polymer-based NPs can help improve the pharmacokinetics and therapeutic efficacy of CNS-targeted drugs [54–56].”
Cancer Nanomedicine: Trends and Future Perspectives
Balkrishna, A., Kumari, A., Jeet, A., Srivastava, D., Sharma, H., Arya, V., Kumar, A., Loveleen, L., Kumari, R., Nimesh, S., et al. (2026) · Springer eBooks · doi:10.1007/978-981-95-6714-0_11 · Cited by 1
Integrated bioelectronics for diagnostic, therapeutic and prognostic oncology
Baghel, S., Agarwal, S., Mashqoor, B., Singh, R., & Sharma, N. K. (2026) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2026.100762
Development of asolectin-based lipid carriers by continuous flow system
Varga, N., Veréb, A., Seres, L., Várkonyi, E. F., Juhász, Á., & Csapó, E. (2026) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2026.140159
Siddheshwar, S. S., Bairagi, S., Mankar, S. D., & Ghorpade, A. C. (2026) · INDIAN DRUGS · doi:10.53879/id.63.02.15629
Biosurfactants’ Importance in Drug Absorption Enhancement
Chaudhary, N. K., Budhathoki, S., Baral, D., Adhikari, J., & Bhattarai, A. (2026) · Sustainable materials and technology · doi:10.1007/978-981-95-4609-1_6 · Cited by 1
Madani, F., Webster, T. J., Nofallah, M., Motamedi, M., Davodabadi, F., Khosravani, M., & Adabi, M. (2026) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2026.3947
Solid lipid nanoparticles in brain targeting
Rajput, A., Wani, S., Kulkarni, S., Pingale, P., & Pingale, A. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36453-2.00006-9 · Cited by 1
Kumar, V., Kakoty, V., & Wadhwa, P. K. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05901-0 · Cited by 1
Alrashidi, A. A., Bahaa, M. M., Eldein, E. E. Z., Ali, A. M. A., Etman, M. A., & Yassin, H. A. (2026) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2026.2673037
“Similar findings have been reported for other SLN-based topical delivery systems, reinforcing the established relationship between zeta potential magnitude and lipid nanoparticle stability (Scioli Montoto et al. 2020; Satapathy et al. 2021; Zhao et al. 2022; Subroto et al. 2023).”
Dual Role of Ginkgo biloba in Nanoparticle Biosynthesis and Parkinson’s Disease Management
Jagaran, K., & Singh, M. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.030
Nagdev, S., Tantray, J., Haswani, N. G., Zawar, L., Patel, S., & Prajapati, B. (2026) · Nano Trends · doi:10.1016/j.nwnano.2026.100214
Bashir, B., andotra, N., Sharma, P., Sharma, T., Chauhan, S., Awasthi, A., Singh, S., Singh, T., Singh, S. K., & Vishwas, S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02271-w
“SLNs are set up from lipid, emulsi-fier and water/ dissolvable that can be utilized by diverse techniques that make SLNs as innovative carrier to deliver drugs to the CNS for treatment of various ND (Satapathy et al. 2021).”
Maity, S., & Remya, P. N. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108543
Dimmito, M. P., Puca, V., Stefano, A. D., Toto, E. C., Corfiati, G., Appignani, M., Grande, R., Marinacci, B., Gallorini, M., Francati, S., et al. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107372 · Cited by 1
Nanocarriers for Brain Targeting: Overcoming the Blood-Brain Barrier in Neuropharmacology
Nishanth, H. V., Tejaswini, S., Devoor, S., Joyson, C., Sneha, H. M., Spoorthi, K., Laharika, K. M., & Dasappa, H. K. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i6.7777
Metadata
- Authors
- Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H.
- Affiliations
- Taipei Medical University (TW)
- Cathay General Hospital (TW)
- Taipei Medical University Hospital (TW)
- Birla Institute of Technology and Science, Pilani (IN)
- Corresponding author
- Yang, Chih-Hao
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-07-31
- Volume
- 13
- Issue
- 8
- Pages
- 1183
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8402065
- OpenAlex
- W3187770666
- Cited by
- 318
- References
- 268
- Citations by year
- 2026: 64 · 2025: 95 · 2024: 70 · 2023: 55 · 2022: 30 · 2021: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-08-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (MOST-106-2320-B-038-049-MY3, MOST-108-2314-B-038-022)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- solid lipid nanoparticles, blood-brain barrier, brain drug delivery, central nervous system disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, brain tumors, epilepsy, ischemic stroke, nanoparticle synthesis, drug carriers, controlled drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.